The Aim of This Study is to Determine the Effectiveness of a Motivational Enhancement Intervention in Reducing Risk Behaviors (Drug and Alcohol Use, Sexual Risk Behavior, Poor Adherence to Medications) Among HIV+ Youth. - 1

This study has been completed.
Sponsor:
Collaborator:
Wayne State University
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00227825
First received: September 27, 2005
Last updated: November 3, 2005
Last verified: September 2005
  Purpose

The purpose of this study is to conduct a pilot study of Motivational Enhancement Therapy (MET), an empirically validated behavioral change strategy, with young adults who are HIV +. The aim is to determine if MET is effective in increasing general health promotion behaviors, adherence to HIV+ specific medical treatment over and above taking medication, and decreasing risky behaviors in young adults who are HIV positive. The longer-term objective is to identify and way to decrease HIV transmission rates, disease progression, illness episodes, and hospitalizations in this high-risk population.

Hypotheses: 1)Youth receiving the motivational intervention plus referrals will report greater reductions in risky behaviors than youth in the control group receiving standard care plus referrals at 3-months post-baseline. This hypothesis will first be tested in the whole sample using an overall risk index. Then, the hypothesis will be tested with each behavior (reduced drug and alcohol use, condom use, taking medications,) within the subgroups reporting problem levels of that behavior; 2)Youth in the intervention group will demonstrate improved viral loads, will report greater improvement in perceived health status, depression, general psychological distress, disclosure to sexual partners, and will demonstrate greater attendance of medical and support service appointments than youth in the control group at 3 months post-baseline; 3)Youth in the intervention group will report greater reductions in temptation to engage in risky behaviors, increased self-efficacy, and improvements in readiness to change their behavior than youth in the control group at 3 months post-baseline; 4)The differences between the intervention and control group from pre- to post- intervention will be maintained at 6, 9, 12, and 15 months post-baseline (3, 6, 9, and 12 months after intervention completion).


Condition Intervention Phase
Adherence
HIV Risk Behaviors
Alcohol & Drug Use
Health Behaviors
Sexual Risk Behaviors
Behavioral: Motivational interviewing
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Motivational Enhancement Therapy to Reduce Risk Behaviors in HIV Infected Youth

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Reduction of Risk Behaviors (Sexual, Drug, & Health), Viral Burden & CD4+ T Cell Count

Secondary Outcome Measures:
  • SES, health beliefs, physical and mental status, self-efficacy, stages of change, service utilization, HIV stigma

Estimated Enrollment: 60
Study Start Date: January 2002
Estimated Study Completion Date: June 2004
Detailed Description:

The proposed study is a randomized clinical trial with a wait-list control. The sample will be 60 HIV+ young adults between the ages of 16 to 24 years recruited from the DMC Horizons Project and other community based HIV programs. Self referred persons meeting the diagnostic criteria of HIV+ will also be accepted. There are no exclusion criteria. Subjects will be randomly assigned to one of 2 groups: MET NOW or MET LATER. MET LATER is the wait list control group. The only difference between the groups is the timing of the intervention and data collection. All subjects will complete 5 research visits and 4 MET therapy sessions. Research visits consists of an interview, completion of self-report questionnaires, a 20cc blood drawn for complete blood count (CBC), viral load and CD4 count, and adherence rating completed by the physician. Established questionnaires are used to measure health behaviors, sexual risk behaviors, substance use, self-efficacy, stage of change, social support, health beliefs, and mental health status. Research visits take about 1 = hours. Therapy sessions consist of MET provided by a trained therapist. Sessions last about 1 hour and focus on changing behavior to improve health, increase medical adherence, and/or reduce risk. Subjects choose the behaviors they want to change. There are a total of 4 sessions over 3 months. The MET NOW group will begin session immediately after the first (baseline) research visit and the MET LATER group will begin therapy sessions approximately 9 months after the first research visit. All subjects will be paid $25.00 for the first research visit with a $5 increase for each subsequent research visit, a total of $175.00 for the 5 research visits. Subjects will receive $10 gift certificate at each therapy session. Cab vouchers or parking fees will be provided for each therapy or research session.

  Eligibility

Ages Eligible for Study:   16 Years to 24 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • A sample of 60 HIV+youth, ages 16-24, will be recruited from the four health care sites in the Michigan Title IV Project.

Exclusion Criteria:

  • In order to increase the likelihood that the current intervention will be easily transportable to real world settings, exclusion criteria are kept to a minimum. No exclusions will be made due to co-morbid mental health problems ( i.e. ADHD, conduct disorder, depression, anxiety disorder), with the exception of thought disorder (i.e. schizophrenia, autism). It is assumed that severe psychosis in conjunction with HIV may require management strategies beyond the scope of the MET interventions (i.e. residential placement). As resources are not available in the current grant to hire and train therapists who are bilingual or translate study questionnaires/measures, subjects will required to speak English fluently. Hispanic or Arabic families who meet this criterion will be included in the study. Currently, all clients at the clinic sites meet this last criterion.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00227825

Locations
United States, Michigan
Detroit Medical Center-CHM and UHC
Detroit, Michigan, United States, 48201
Sponsors and Collaborators
Wayne State University
Investigators
Principal Investigator: Sylvie Naar-King, Ph.D. Wayne State University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00227825     History of Changes
Other Study ID Numbers: NIDA-14710-1, R21-14710-1
Study First Received: September 27, 2005
Last Updated: November 3, 2005
Health Authority: United States: Federal Government

ClinicalTrials.gov processed this record on October 01, 2014